Apoptosis

Shop By

Items 101-150 of 257

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. MDMX inhibitor

    SJ 172550 is the first MDMX inhibitor with EC50 of 0.84 uM; binds reversibly to MDMX and effectively kills retinoblastoma cells in which the expression of MDMX is amplified.
  2. Caspase inhibitor

    BOC-D-FMK is a Novel inhibitor of Caspase-3.
  3. MDM2 inhibitor

    MI-773 is an orally available MDM2 antagonist with Ki of 0.88 nM.
  4. elastogenesis inhibitor

    L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor.
  5. MCL-1 inhibitor

    A-1210477 is a potent and selective MCL-1 inhibitor. A-1210477 induces the hallmarks of intrinsic apoptosis and demonstrates single agent killing of multiple myeloma and non-small cell lung cancer cell lines.
  6. Caspase Inhibitor

    Ac-DEVD-CHO is an aldehyde peptide and a CPP32/Apopain Inhibitor.
  7. ASK1 inhibitor

    Selonsertib is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.
  8. BCL-XL inhibitor

    A-1155463 is a highly potent and selective BCL-XL inhibitor, A-1155463 shows picomolar binding affinity to BCL-XL (Ki = <0.01 nM), and >1000-fold weaker binding to BCL-2 (Ki = 80 nM) and related proteins BCL-W (Ki = 19 nM) and MCL-1 (Ki > 440 nM)
  9. BCL-XL inhibitor

    A-1331852 is a potent and selective BCL-XL inhibitor. BCL-XL is the major antiapoptotic survival protein and may be a novel therapeutic target in CML.
  10. BCL6 inhibitor

    CID5721353 is a B-Cell Lymphoma 6 Inhibitor (BCL6 inhibitor).
  11. RIP2 kinase inhibitor

    GSK583 is a highly potent and selective inhibitor of RIP2 Kinase.
  12. RIP2 kinase inhibitor

    RIP2 kinase inhibitor 1 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.
  13. RIP2 kinase inhibitor

    RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9.
  14. Bcl-2 inhibitor

    Apogossypolone is a nonpeptidic small-molecule inhibitor of Bcl-2 with
  15. Mcl-1 inhibitor

    MIM1 is a selective small molecule inhibitor of Mcl-1(IC50= 4.8 μM) that overcomes Mcl-1-dependent leukemia cell survival.
  16. Bcl-2 family inhibitor

    (+)-Apogossypol is a potent inhibitor of Bcl-2 family proteins; competing with the BH3 peptide-binding sites on Bcl-2, Bcl-XL, Mcl-1, Bcl-W, and Bcl-B, but not Bfl-1, with IC50s of 0.5 to 2 μM.
  17. Caspase-1 inhibitor

    Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.
  18. PKD Inhibitor

    CRT-0066101, potent inhibitor of protein kinase D (PKD); inhibits all PKD isoforms (IC50 values are 1, 2 and 2.5 nM for PKD1, PKD3 and PKD2 respectively).
  19. (S)-Gossypol acetic acid is a inhibitor of Bcl-2, potently induce cell death in Jurkat cells overexpressing Bcl-2 (IC50, 18.1μM) or Bcl-xL (IC50, 22.9μM).
  20. MDM2 inhibitor

    NVP-CGM097 is a potent and selective MDM2 inhibitor; an orally bioavailable HDM2 antagonist with potential antineoplastic activity.
  21. Caspase inhibitor

    Z-VAD(OH)-FMK is an irreversible tripeptide inhibitor of all caspases.
  22. MDM2/XIAP inhibitor

    MX-69 is the MDM2/XIAP inhibitor, used for cancer treatment.
  23. Mcl-1 inhibitor

    Pyridoclax is a potent Mcl-1 inhibitor with Kd value of 25 nM.
  24. Cysteine protease inhibitor

    Z-FA-FMK is an irreversible inhibitor of cysteine protease
  25. GGTase I inhibitor

    GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit Rap1A with IC50 of 3 μM; little effect on Ha-Ras with IC50 of >20 μM.
  26. MDM2 inhibitor

    HDM201 is a novel, highly potent and selective inhibitor of the p53-Mdm2 interaction with affinity constant for Mdm2 in the picomolar range and a selectivity ratio greater than 10000-fold vs Mdm4.
  27. p53 activator / NF-κB inhibitor

    CBL0137(CBL-0137) activates p53 and inhibits NF-kB with EC50s of 0.37 μM and 0.47 μM in the cell-based p53 and NF-kB reporter assays, respectively. It also inhibits histone chaperone FACT (facilitates chromatin transcription complex).
  28. Mcl-1 inhibitor

    AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC50 of 0.7 nM in FRET assay and a Kd of 0.17 nM in surface plasmon resonance (SPR) assay.
  29. CYP51 inhibitor

    Tebuconazole is a triazole fungicide used agriculturally to treat plant pathogenic fungi.
  30. XIAP inhibitor

    ASTX660 is an orally bioavailable, non-peptidomimetic antagonist of both X chromosome-linked inhibitor of apoptosis protein (XIAP) and cellular IAP 1 (cIAP1), with potential antineoplastic and pro-apoptoticctivities. 1799328-86-1 (free base) 1799328-50-9 (HCl) 1799328-90-7 (mesylate) 1799328-88-3 (sulfate)
  31. MPO inhibitor

    AZD-5904 is a potent orally bioavailable MPO inhibitor. In preclinical studies, AZD-5904 inhibited the isolated MPO enzyme with an IC50 of 140 nM and was approximately equipotent in assays of rat and mouse MPO enzyme activity.
  32. Bcl-XL inhibitor

    A-385358 is an inhibitor of Bcl-XL that enhances the in vitro cytotoxic activity of numerous chemotherapeutic agents (paclitaxel, etoposide, cisplatin, and doxorubicin) in several tumor cell lines.
  33. BCL6 inhibitor

    FX1 is an inhibitor of the transcription factor B cell lymphoma 6 (BCL6) with IC50 value of ~35 μM.
  34. nuclear transport receptor importin-β inhibitor

    Importazole is a cell-permeable inhibitor of importin-β. It specifically inhibits the function of importin-β, likely by altering its interaction with RanGTP.
  35. FACT inhibitor

    CBL0137 is a FACT inhibitor that functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death.
  36. Bcl-2/Bcl-XL inhibitor

    AZD-4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor.
  37. Mcl-1 inhibitor

    Marinopyrrole A, aslo known as Maritoclax, is a selective inhibitor of Mcl-1 with IC50 value of 10.1μM.
  38. pan-caspase inhibitor

    MX1013 is a dipeptide pan-caspase inhibitor that inhibits caspase-1, caspase-3, and caspase-6, 7, 8, and 9.
  39. NGF inhibitor

    Ro 08-2750 is a potent and selective Nerve growth factor (NGF) inhibitor that binds the NGF dimer (KD ~ 1 μM).
  40. ER stress inhibitor

    Tauroursodeoxycholate (TUDCA; UR 906; Taurolite) is an endoplasmic reticulum (ER) stress inhibitor.
  41. multi-targeted tyrosine kinase inhibitor

    Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
  42. TNF receptor inhibitor

    AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). Inhibiting an immediate TCR signal has promise for treating a broad spectrum of human T cell-mediated autoimmune and inflammatory diseases.
  43. RIP1 kinase inhibitor

    GSK963 is a chiral, highly potent and selective inhibitor of RIP1 kinase, with an IC50 of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro.
  44. BCKDC kinase (BDK) inhibitor

    BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM.
  45. myeloid cell leukemia 1 (MCL1) inhibitor

    S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor with a Kd of 0.19 nM for human MCL1.
  46. Mcl-1 inhibitor

    (R)-MIK665 is the less active enantiomer of MIK665. MIK665 is a special Mcl-1 inhibitor with an IC50 of 1.81 nM.
  47. MCL-1 inhibitor

    AMG-176 is a potent, selective and orally bioavailable MCL-1 inhibitor, with a Ki of 0.13 nM.
  48. BCL-2 inhibitor

    S55746 (BLC201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BLC201) has antitumor activity with low toxicity.
  49. Mcl-1 inhibitor

    MIK665 (S-64315) is a special Mcl-1 inhibitor extracted from patent WO2016207225A1, compound Preparation 13, has an IC50 of 1.81 nM.
  50. MCL-1 Inhibitor

    VU661013 is a MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia.

Items 101-150 of 257

per page
Set Descending Direction